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Abstract 
Protein domains are highly conserved functional units of proteins. Because they carry 
functionally significant information, the majority of the coding disease variants are located on 
domains. Additionally, domains are specific units of the proteins that can be targeted for drug 
delivery purposes. Here, using information about variants sites associated with diseases, a 
disease network was built, based on their sharing the same domain and domain variation site. 
The result was 49,990 disease pairs linked by domain variant site and 533,687 disease pairs that 
share the same mutated domain. These pairs were compared to disease pairs made using previous 
methods such as gene identity and gene variant site identity, which revealed that over 8,000 of 
these pairs were not only missing from the gene pairings but also not found commonly together 
in literature. The disease network was analyzed from their disease subject categories, which 
when compared to the gene-based disease network revealed that the domain method results in 
higher number of connections across disease categories versus within a disease category. Further, 
a study into the drug repurposing possibilities of the disease network created using domain 
revealed that 16,902 of the disease pairs had a drug reported for one disease but not the other, 
highlighting the drug repurposing potential of this new methodology. 
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1. Introduction 
 
Protein domains are structural units of proteins that are highly conserved and functionally 
identical across species1,2.  Domains are crucial for proper protein function, as such, variations in 
protein domains can have consequential impact on an organism’s phenotype3,4. Additionally, 
recent studies have shown that disease variations tend to cluster in the same domain sites of 
different genes, forming hotspots of disease variations5-7. The identification of these disease 
domain relationships provides potential for developing novel hypothesis about the molecular 
underpinning of diseases, that were not visible in similar gene-centric approaches. Here, we 
introduce a new methodology, DomainScope, that uses disease associated mutated protein 
domains to establish relationships between phenotypes. DomainScope provides the framework to 
create domain-based disease networks and thereby reveals non-obvious mechanistic and 
functional similarities between human disorders.  
The study of relationships between human diseases is an important step towards making 
advancement in personalized medicine, drug repurposing, and disease research8-10.  This 
relational study has been enriched by the increased availability of health and disease information. 
The curation of various disease relationship has culminated in the building of disease networks. 
These networks are built using various features of diseases, namely: gene associations and 
expression 11-13, protein interaction14, pathways15,16, etiology17, semantic similarity18.  As well as 
some hybrid approaches which integrate these features to build more robust disease 
networks19,20. These types of networks have been used to understand the origin of particular 
diseases21,22 as well as drug repurposing23-25. Though each of these networks reveal various novel 
relational information, one of the remaining challenges in disease network research is 
introducing new molecular information, which in turn will lead to new hypotheses about 
molecular relationships between diseases. DomainScope does this by introducing domain disease 
relational information to the network medicine field.  
By looking at domain-based disease connections, as we do with DomainScope, we expect to gain 
more insight into functional origins of phenotypes.  Our method mapped variations from over 
80,000 disease phenotypes from Online Mendelian Inheritance in Man (OMIM)26, ClinVar 
database27, Universal Protein Resource (UniProt)28, and Human Gene Mutation Database 
(HGMD) 29 to their protein domain. Each domain was then associated to a disease Unified 
Medical Language System’s (UMLS) Concept Unique Identifier (CUI) resulting in the 
identification of disease relationships among CUIs based on identities at both the domain and the 
domain variation site levels.   
The DomainScope method yielded 533,687 disease pairs based on domain-disease associations, 
and 49,990 disease pairs based on disease variants associated to the same protein domain and 
variation site.  Our domain-based results were compared with previously explored methods that 
built disease networks based on gene commonalities. Due to the potential of the same domain 
being found in variety of tissues30, as opposed to the generally localized nature of a gene,  
DomainScope has resulted in identifying disease pair relationships that may have not been 
obvious with a gene or even pathway approach.  
The pairings made by our domain approach were further explored with relation to their Medical 
Subject Headings (MeSH) disease categories. Contrasting with results from previous approaches 
many of the diseases pairs made by DomainScope stretched across disease categories as opposed 
to pairings within same categories. Furthermore, many of the disease pairs identified by 
DomainScope were missing from previous gene-based approaches. Over 8,000 of the 
DomainScope disease connections found by looking at identity of domain and variation site 
between diseases were from different genes and rarely found together in literature, indicating 
their non-obvious nature.  
These novel connections made by using DomainScope can lead to discovery of new therapeutic 
methods. Of the 49,990 disease pairs16,902 have a drug identified in one of the two disease pairs 
and not the other indicating their potential for drug repurposing.  
2. Materials and Methods 
 
2.1 Building the Variation dataset 
 
The disease variant tables compiled previously in Peterson et al.31, from OMIM, ClinVar, UniProt 
and HGMD were used to extract variant-disease relationships. These variants were mapped to 
disease/disorder concepts from UMLS32 categorized into unique identifier concepts or CUIs. CUIs 
are categorically assigned to biological phenotypes and maintain the disease categorization, where 
applicable15. Additionally, MeSH categories were also incorporated into the dataset, automatically, 
providing disease type categorization following the methodology presented in Cirincione et al15. 
Using these two features, CUI and MeSH, allows us to categorize the dataset for a comprehensive 
understanding of domain disease connections.  
 
2.2 Mapping disease variations to domains 
 
Here, we used the approach previously used to create our Domain Mapping of Disease  Mutations  
(DMDM) to map all human proteins, from protein data found in UniProt33 to all protein domains 
from the CDD database.34 Once each gene variation position was aligned to a representative 
protein (larger gene isoform from RefSeq), the HMMer’s semi-global implementation35 was used 
to map to a domain and position using Position Specific Mappings (PSSMs) from curated CDD 
domains, Pfam36, Smart37 and COGs38. Resulting in the associated domain and domain position 
being marked per disease variation as shown in Figure 1 on each protein.   
 
Figure 1 Two different proteins that have disease causing variations in same domain positions. This allows for a mechanism by which the diseases can 
be related. 
2.3 Constructing the bipartite network of genes or protein domain associations to disease  
 
The many to many relationships between gene, gene site, domain, and domain sites with disorders 
was created from the initial dataset of human disease variants and the mapping of these variants to 
a highly redundant set of protein domains (as described in previous section). As a result,  the human 
variant dataset with domain associations contained almost 1.8 million disease gene variants entries 
mapped protein domains,  with various information about the disease, including, the disease 
identifier in UMLS (CUI) with its corresponding disease name, the variant location at protein and 
protein domain level, and the MeSH category of the CUI.   
Using the gene associations, a network of disease-disease connections was made based on gene 
identity and identical gene variation positions. 
Similarly, two variants in the same protein domain constitute the basis of disease associations used 
in DomainScope at protein domain level, with a stricter requirement for the two variants to be in 
identical protein domain positions used in DomainScope at domain position level. This domain 
pairing involved 139,522 unique domain variation sites across 3,673 domains. Although some of 
the domains may be redundant due to the inherit redundancy between the pfam, COGs, CDD, 
Smart datasets. The initial database of all CUI pairs, each pairing one CUI to another based on 
identity of domain and domain variation contained several repetitions of CUI1-CUI2 pairing by 
different domain position variations. For simplicity, the connections were non-redundified to 
represent only one of each of the CUI-CUI pairs in the non-redundant domain and domain site 
disease datasets.  
All disease connections were associated to their corresponding MeSH categories based on the CUI-
MeSH mapping provided by UMLS. 
 
 
 
 
 
 
 
2.4 Domain site functional analysis 
 
To identify the functional sites that are involved in making disease pairs based on identical domain 
sites, we looked more closely at the functional features of the sites in the CDD domains. A subset 
of the CDD, the cd manually curated domains, were chosen as these are the ones with the 
Figure 2 Overview of network building mechanism. a- Disease connected by similar domain sites. b- Network generated by disease 
connections. 
a b 
functional site annotations from our dataset34. The 3.3 million disease pairs spanned 107,267 
unique domain sites which were in 1,997 unique domains. To remove the effect from the high 
redundancy of the disease-domain mappings, i.e., most domains from a large cd cluster will map 
to the same disease variant, cd domains were mapped to their root cd domain and only the results 
of  mapping  functional sites to this root domain were used in our analysis. This resulted in 16,825 
unique root function which were further categorized in their common type designation39: active, 
polypeptide binding site, loop, motif, nucleic acid binding, ion binding, chemical binding, 
postranslational modification and other (walker, box, etc). 
 
2.5 DomainScope network visualization 
 
Once the data was parsed and analyzed, networks were created linking the CUI-CUI pairs (Figure 
2), using Cytoscape40. For ease of visualization, the CUI’s were reduced to their MeSH categories 
and mapped as entities within MeSH categories (Figure 4). For this visualization, if a CUI had 
multiple MeSH categories it was included in all its categories. For example, Kallman syndrome 2 
(C1563720) is in urological and male genital diseases (C12), female genital diseases and 
pregnancy complications (C13), congenital, herditary and neonatal disease and abnormalities 
(C16), and endocrine system diseases (C19). The thickness of the edges was calculated based on 
the number of connections between the two MeSH nodes, while the size of the nodes was the 
number of CUIs in that category. If two disease forming a CUI-CUI pair were in the same MeSH 
category they would be part of the self-connected loop existing on most nodes. Additionally, 
MeSH categories with low number of CUIs, bacterial infections and mycoses (C01), virus diseases 
(C02), parasite diseases (C03), disorders of environmental origin (C21) and pathological 
conditions, sign and symptoms (C22) were excluded from our analysis. On the other hand, 
congenital, hereditary and neonatal disease and abnormalities (C16), was also excluded because 
almost all diseases fall into this category, lacking the specificity that the other MeSH categories 
provide. The gene network was also visualized. Using the NetworkAnalyzer in cytoscape, the 
network statistics of both networks were calculated. 
 
2.6 Heatmap of gene-based disease relationships and domain variation based 
 
Based on the disease connections of both whole gene and domain site approaches, the combination 
of the corresponding MeSH categories to each disease pair, i.e., CUI1 and CUI2 was summed. 
Fisher’s test was used to estimate each of the heatmap’s cell P-values for gene and domain site 
CUI-CUI pairs, Figure S1. Like the disease network, if a disease was in multiple categories it was 
counted as a part of both categories.   
 
2.7 PubMed disease mapping 
Each CUI was used as a search term in PubMed41 to create CUI-PMIDS database, using E-
utilities tools42. Based on the disease pairs identified by the various approaches (gene, gene and 
position, domain, domain and position) the Jaccard overlap Index was estimated for each CUI 
pair. A criterion of minimum of 500 publications associated to each CUI and a Jacckard overlap 
index below 5 % was used to identify a CUI-CUI pairs of interest, i.e., non-obvious disease pairs 
based on publication evidence.  
 
2.8 Drug- gene and disease mapping 
Drug information was collected from two separate databases, DrugBank43 and RxNorm44. The 
DrugBank database was parsed to identify drugs associated to a CUI using its gene information. 
With the RxNorm database, each CUI was converted to its NDF-RT identifier and the RxClass 
API was used to identify all drugs associated with the NDF-RT identifier using the “may_treat” 
relation. The resulting RxCUIs were converted to their corresponding DrugBank identifier. 
Based on the drugs identified through DrugBank and RxNorm, CUI-CUI pairs with common 
drugs were identified. 
3. Results 
Using DomainScope we were able to form disease pairs in two ways, as follows. Based on 
domain identity, which resulted in 533,587 disease pairs, and a more restricted way that resulted 
on 49,990 disease pairs associated to variants in identical protein domain positions. 
DomainScope results were compared with the gene-based diseaseome,  which for our database 
resulted in 163,492 unique diseases pairs if the match was based on the diseases associations at 
the same gene regardless of the variant position and a total of 6,673 disease pairs matched based 
on identical gene positions. 
The result of the analysis at the domain-site level was the identification of 49,990 disease pairs 
among 3,673 different domains. To understand the types of domains involved, the domain 
functional annotations were considered using a non-redundant set of CDD domains with 
functional annotation consisting of 1,997 CDD domains, though some of these 1,997 had 
multiple positions that related two diseases.  
The results from the domain site-based analysis were further analyzed to categorize the type of 
functional sites where the disease connections occur. Results of such study were restricted to root 
domains from the CDD, which provided a non-redundant set of domains with functional 
annotation. Our analysis shows that a total of 16,825 functional feature sites from these CDDs 
were responsible for disease pairings. Figure 3 shows the frequency of these 16,825 features as 
categorizing by their functional groups (active, polypeptide binding site, loop, motif, nucleic acid 
binding, ion binding, chemical binding, postranslational modification and other (walker, box 
etc)). More detailed distribution of domain positions and functional annotations is available in 
Appendix T1. 
 
Figure 3 Distribution of domain based on root level functional annotations 
 
The network of domain-variant site disease pairs, clustered by MeSH categories, is shown in 
Figure 4. Each node represents a MeSH category and the thickness of the lines represents number 
of unique CUI connected that pertained to specific MeSH categories. The size of the node indicates 
the number of disease or unique CUIs that pertained to that category. One CUI may belong to 
many MeSH categories, for Figure 4 each instance of the CUI-MeSH pair was counted 
individually. For a complete list of MeSH distributions see Appendix T2.  
 
 
Figure 4. Overall disease network divided into MeSH categories. Size of node represents number of diseases in that category, 
edge thickness represents number of diseases involved in the connections between those two diseases. 
The MeSH category connectivity of disease pairs were compared between the domain variation 
site approach and the gene approach. The results show, the domain variation approach has a higher 
tendency to connect diseases across all categories, showing a over 128,000 disease connections 
across disease categories, compared to 24,500 found in the gene-based network approach. The 
discrepancy between the totals here compared to the total connections made by gene or domains 
is due to two reasons, one being the lack of MeSH categorization for certain diseases and two 
being the multiplicity of categorization for certain diseases. Subsequently, p-values were 
calculated for the two approaches as shown in Figure S1. Based on the p-values, a study of the 
categorical connections in the gene and domain approaches shows that gene categories tend to 
cluster between diseases from the same categories. The gene approach revealed 20 stastically 
significant MeSH clusters while the domain approach has only 3 statistically significant cluster. 
Furthermore, the potential drug repurposing applications for the domain-site level approach were 
considered. Out of the 49,990 disease pairs made at domain site-level, 11,601 shared the same 
drug treatment and 16,902 pairs have at least one drug treatment associated to the disease or gene 
for one of the disease pairs and none for the other.  
 Figure 5 Disease-Disease pairs that share one CUI that is Parkinson’s Disease. The related CUI pair is organized in its MeSH 
category. If a CUI had two mesh categories it was colored according to the higher mesh category but placed in the group of the 
lower mesh category. The dark grey nodes represent CUI’s that had more than two unique mesh categories. 
 
3.1 Case Study: Parkinson’s case  
To demonstrate the ability of this method in discovering non-obvious disease relationships the 
Parkinson’s disease (PD) case was chosen, Figure 5. The center of the figure represents various 
CUI found in the UMLS database to represent PD. Each of the outside nodes represent a unique 
CUI that is connected to PD through a shared domain variation site. The CUI’s are organized in 
their respective MeSH categories. Where a CUI has two MeSH categories it was colored 
according to the higher MeSH category but placed in the group of the lower MeSH category. The 
dark grey nodes represent CUIs that had more than two unique MeSH categories. In total there 
are 452 CUI pairs that resulted from this, with 202 of these pairs being novel based on the 
Jaccard calculations described in section 2.7. Looking at the drug reproducibility application, our 
analysis reveals that 300 of the disease pairs that involve PD have a known drug in the other 
disease pair. 
 
  
 
 
 
 
 
 
 
 
4. Discussion 
We introduce a novel methodology which compares the domain-variant associations of two 
disease phenotypes to identify disease relations. This method has great potential for discovering 
common molecular connections and drug targets among diseases that could lead to harvesting 
new therapeutical treatments and biomarkers for diagnosis and prognosis of human diseases. To 
better understand the value of this approach, we compare it with previously explored gene-
centric approach and show the advantages of using the domain-level approach. 
Using a protein domain-based approach, the number of disease-disease connections that can be 
made varies from 533,687, when the variant being in a common domain is used to connect 
diseases, to 49,990 when the more strict requirement, the variants from each diseases should be 
in the same domain position, is used. In contrast, when the diseases are connected using the 
condition that the variants are in the same gene, 163,492 disease connections are made with only 
6,673 of the variants in the same gene-position.  
The domain site-based disease network (Figure 4) recapitulates some of the original findings in 
gene-based  networks, namely the high connectivity of diseases within the same broad category.  
However, because the network does not take into account the difference in the number of 
diseaseses per category, p-values were calculated which show that the gene approach has more 
significant p-values, most of which are in the self similarity categories. Additionally, our 
approach tends have a higher tendency to connect diseases across all categories, showing over 
86% disease connections across disease categories, compared to 70% found in the gene-based 
network approach.  
Figure 6  The structure of the Chain A, Serine/threonine-protein Kinase Nek2 (PDB 2W5A_A) representative of the 
CDD cd08215 is shown with position 17 highlighted in red. Cd 08215,Position 17 was mapped to position 257  in 
PINK1 and  27 in TSSK2 associate 
  
 
 
 
 
 
 
 
Table 1 Cytoscape NetworkAnalyzer results for the domain variant position based disease network and 
the gene disease network 
 
To compare gene-gene disease network vs the domain variation site disease network, the 
network metrics were calculated in cytoscape and shown in Table 1. This analysis shows that the 
clustering coefficient of the domain network is lower than that of the gene network. Further, the 
hetreogeneity of the gene network was higher, reflectiving its greater hubbness.  
Our results also show a larger number of “novel” disease connections found using the domain 
approaces versus gene based approaches. Here we defined a novel disease pair based on their co-
occurrence in literature (see details in section 2.7). When using  the domain-based approaches to 
build connections between diseases, we found 38,500 disease pairs with Jaccard index less than 
5% when whole domain were used to connect and 8,618 when the more strict, same domain-site, 
criteria was used to build the connections. As expected, gene-based approaches, which contained 
less pairs across disease categories, produced a much smaller number of novel connections, 
2,314 when using whole gene and only 268 when variations are in the same gene position. Table 
2 highlights results for the domain-site based analysis showing the top disease pairs (22 CUI 
pairs) forming 100 or more novel connections. 
 
 
 
 
 
 
 
 Domain based disease 
network 
Gene based disease 
network 
Number of 
nodes 
5287 5298 
Network 
heterogeneity  
1.932 2.224 
Network 
density 
0.004 0.012 
Connected 
component  
179 344 
Clustering 
coefficient  
0.650 0.792 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Top 22 diseases, and their corresponding CUI, that are involved in novel disease pairings using 
the domain variation site identity method. Novelty established using Jaccard index, based on PubMed 
publications  
When comparing the location of disease connections, as shown in Table 3 gene-level 
connections are more concentrated in Hemoglobins, while the domain connections are located in 
Kinase domains. Roughly 70% of disease-gene pairs are made with Hemoglobin genes, though 
this may be a result of the biases in the Mendelian disease set included. Furthermore, polypeptide 
binding sites are largely responsible for the disease pairings. These sites have great implications 
on potential drug docking sites45 which could drive drug discovery.  
  
CUI Disease Name Novel Connections  
C0035334 Retinitis Pigmentosa 231 
C0011860 Diabetes Mellitus, Non-Insulin-Dependent 185 
C0162809 Kallmann Syndrome 184 
C0339527 Leber Congenital Amaurosis 170 
C1563720 Kallmann Syndrome 2 (disorder) 162 
C0007193 Cardiomyopathy, Dilated 156 
C0001768 Agammaglobulinemia 141 
C0004352 Autistic Disorder 140 
C0019569 Hirschsprung Disease 140 
C0018553 Hamartoma Syndrome, Multiple 136 
C0010273 Craniofacial Dysostosis 135 
C0220658 Pfeiffer Syndrome 133 
C0002768 Congenital Pain Insensitivity 128 
C0221026 X-linked agammaglobulinemia 125 
C0376358 Malignant neoplasm of prostate 121 
C0030567 Parkinson Disease 121 
C0031269 Peutz-Jeghers Syndrome 118 
C0007194 Hypertrophic Cardiomyopathy 114 
C0010278 Craniosynostosis 114 
C0021655 Insulin Resistance 110 
C0020074 HSAN Type IV 110 
C0006142 Malignant neoplasm of breast 108 
 Gene 
 
Number of Disease 
Connections 
Percentage of 
Disease Connections 
HBB 112101 0.677 
HBA1 26106 0.158 
HBA2 3240 0.020 
G6PD 3003 0.018 
ALB 1176 0.007 
SERPINA1 780 0.005 
HBD 666 0.004 
TP53 561 0.003 
APOE 496 0.003 
FGFR3 406 0.002 
Domain Root 
cd13968:PKc_like 734574 0.898 
cd00267:ABC_ATPase 28659 0.035 
cd00882:Ras_like_GT 7154 0.009 
cd06916:NR_DBD_like 6283 0.008 
cd01067:Globin_like 6694 0.008 
cd00096:Ig 6008 0.008 
cd06157:NR_LBD 5208 0.007 
cd00172:SERPIN 3336 0.004 
cd06534:ALDH-SF 1487 0.002 
cd01363:Motor_domain 1711 0.002 
Table 3 Gene, Domain Root distribution of disease pairs 
As shown in our previous discussion, one of the domain-based approaches main advantage, over 
gene and pathways, is its ability to connect apparently unrelated genes regardless of where they 
are expressed, which is also shown in the following case study. For this case study we looked 
specifically at PD ( Figure 5) where the connections between PD are rather well distrbuted 
among all disease categories. However, a majority of the disease fell in the neoplasmas (C04) 
and nervous system diseases (C10), forming also interesting connections with less predictable 
categories such as urological and male genital diasese (C12). One example of such connections 
was a result of a domain variation in two different genes, PINK1 and TSSK2, connecting PD and 
male infertility. This pairing was made through variants in the same protein domain position of 
the Serine-Threonin kinase (cd08215, position 17). Figure 6 highlights the structural similiarities 
of the variations in the genes PINK1 and TSSK2, which were made through the same domain 
site, regardless of the fact that the original disease data was from variants in genes without 
common cannonical pathways and that are expressed in different tissues, i.e., brain and testis.  
The structure for the catalytic domain  of the Serine/Threonine Kinase ( cd08215) is represented 
by the Serine/Threonine-protein Kinase Nek2, chain A ( PDB code 2W5A_A), the active site, 
including the ATP site is highlighted in yellow with the variation in position 17 of cd08215 
highlighted in red. This exemplifies the ability of our method to uncover the specific site or 
domain where the diseases match, providing valuable information for drug discovery. 
Furthermore, of all the PD connections, 300 have a discovered drug therapy, and some of these 
drug therapies have previously been shown to be applicable for PD. For example Zhao et al46 
showed the drug repurposing potential between PD and Asthma, Alzheimer disease, Depression, 
Epilepsy, Multiple scleroris, Fatigue and Immunological disorders. Of these, Multiple sclerosis, 
immunological disorders and eplipesy were all part of the pairings discovered by our method too, 
giving further justifications for the domain-based pairings resulting in drug repurposing. Other 
studies 47 have drawn drug repurposing connections between PD and respiratory diseases, which 
was also shown in our domain connections. Thus, our results shows the ability of DomainScope 
to identify PD pairings that are not currently reported in the literature, such as male infertility, 
while veryfing several of the previously discovered PD-pairs with drug repurposing value.  
5. Conclusions 
The DomainScope approach introduced in this work provides a novel framework to considerable 
expand the number of disease connections made based on the molecular patterns of the variants 
associated to the disease. In particular, the specific domain site modality provides a way to 
prioritize disease connections for drug repurposing or other applications for which identiying the 
function of the specific site aids in the molecular modelling of drugs targets and disease 
mechanism. The case specific study in Parkinson Disease shows that our methodology uncovers 
many unknown disease connections through similarities at the protein domain level addressing 
the need to generate new molecular hypotheses for PD, and other diseases, for which new 
treatements are needed.   
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